Spotlight On... Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer; Bristol-Myers' Daklinza wins access to bigger hep C market; Cigna inks outcomes-linked deal on Novartis' Entresto; and more...

Pfizer's ($PFE) Ibrance has already been prescribed to more than 20,000 patients, and the company says it has a "very heavy" clinical trial program testing it in multiple types of breast cancer and beyond. But Pfizer may need that head start and more to stay ahead of a pair of up-and-comers currently in its rivals' pipelines. More from FiercePharmaMarketing

@FiercePharma: Report: Veterinary prices rise modestly as clinics charge more for routine services. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: FDA shoots down Vertex's latest bid for Kalydeco expansion. Article | Follow @CarlyHFierce

> The FDA green-lighted Bristol-Myers Squibb's ($BMY) Daklinza for more hard-to-treat hep C patients. Release

> Cigna announced that it has entered into an outcomes-based contract with Novartis ($NVS) over heart-failure newcomer Entresto. More

> Top FDA official Janet Woodcock told a congressional committee that she's expecting a deluge of biosimilars applications and may need more resources to handle them. Report

> The U.S. Justice Department is investigating possible fraud among compounding pharmacies that hawk pricey pain-relief creams. Report

Medical Device News

@FierceMedDev: ICYMI: Nikon makes strategic investment in Thiel-backed cheap, safe handheld X-ray startup. Article | Follow @FierceMedDev

@EmilyWFierce: PhRMA is planning on spending millions this year to clean up the drug industry's tarnished rep. More from the WSJ (sub. req.) | Follow @EmilyWFierce

> U.K. engineering company Halma purchases maker of real-time hospital monitors for $140M. Story

> Former BD CEO backs Velano Vascular in $3.5M for needle-free blood draw device. Article

Biotech News

@FierceBiotech: Baxalta partner CTI plunges after FDA slaps partial hold on PhIII myelofibrosis drug. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: UPDATED: A patient in Akashi's suspended Duchenne MD trial dies. More | Follow @JohnCFierce

> Biogen joins a GSK-led data-sharing project to make R&D more efficient. Report

> Sarepta faces another FDA delay with its much-scrutinized DMD drug. Story

> AstraZeneca's cancer checkpoint combo looks promising in small lung cancer study. Article

Animal Health News

> Scientists pinpoint contributions pets can make to human medicine. Report

> Currency woes overshadow Merck's 2015 growth in animal health. Item

> UPenn veterinary students to star in new Animal Planet reality show. Story

> Report: Veterinary prices rise modestly as clinics charge more for routine services. More

> Stem cell therapy developed to treat dental disease in cats could also help people. Article

Biotech IT News

> 454 Life Sciences, Ion Torrent founder raises $40M for tech-enabled drug development shop. Report

> In silico discovery platform drives forward Bavarian Nordic's MRSA vaccine program. More

> Buzz: Roche weighing up bid for Pacific Biosciences. Item

> U.K. looks to house software developers at planned cancer research hub. Story

> Illumina signs biobank deals to fuse genome data, EMRs. Article

Pharma Marketing News

> Docs take aim at Novartis' 'horrifying' Entresto ad. Article

> Valeant, AstraZeneca played the Super Bowl ad game, but did they win? Item

> GSK's slow-off-the-blocks Anoro gets a leg up from Incruse sidekick. Story

> Omega diet-aid ad banned in U.K.; summer slimming promos not 'socially responsible.' Article

> 'Safe' social network LinkedIn emerges as popular marketing tool for pharma. Report

And Finally... Merck & Co.'s ($MRK) recent Vioxx-related settlement in New Jersey is expected to trigger a $150 million hit to the directors' and officers' insurance market. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.